• Explore /
  • Poster
  • / Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.

Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.

Abstract Poster

Authors

TAKAHIRO KOGAWA

Takahiro Kogawa

National Cancer Center Hospital East, Chiba, Japan

Takahiro Kogawa , Emi Noguchi , Takashi Yamanaka , Naohito Yamamoto , Chi-Feng Chung , Yen-Shen Lu , Dwan-Ying Chang , Joohyuk Sohn , Gun Min Kim , Kyung-Hun Lee , Soo-Chin Lee , Yoon Sim Yap , Yoshiko Umeyama , Kazuki Sudo , Tomomi Hata , Aya Kuchiba , Taro Shibata , Kenichi Nakamura , Kenji Tamura , Kan Yonemori

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03423199

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA1068)

DOI

10.1200/JCO.2023.41.17_suppl.LBA1068

Abstract #

LBA1068

Poster Bd #

289

Abstract Disclosures

Similar Posters

First Author: Aditya Bardia

First Author: Tomás Pascual

First Author: Seock-Ah Im

First Author: Nusrat Jahan